[CH3:1][O:2][C:3]1[CH:4]=[C:5]([C:15]2[C:19]3[CH2:20][CH2:21][CH2:22][C:23](=[O:24])[C:18]=3[O:17][N:16]=2)[CH:6]=[CH:7][C:8]=1[N:9]1[CH:13]=[C:12]([CH3:14])[N:11]=[CH:10]1.[BH4-].[Na+].O.C(OCC)(=O)C>C1COCC1.CCO>[CH3:1][O:2][C:3]1[CH:4]=[C:5]([C:15]2[C:19]3[CH2:20][CH2:21][CH2:22][CH:23]([OH:24])[C:18]=3[O:17][N:16]=2)[CH:6]=[CH:7][C:8]=1[N:9]1[CH:13]=[C:12]([CH3:14])[N:11]=[CH:10]1To the 3-(3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl)-5,6-dihydrobenzo[d]isoxazol-7(4H)-one (7.16 mg, 2.22 mmol) in THF/EtOH (v/v=1:1, 26 ml) at ° C., was added NaBH4 (101 mg, 1.66 mmol). The reaction mixture was stirred for 30 min before careful addition of water and extraction with ethyl acetate. The organic phase was washed with water and brine, dried over MgSO4 and concentrated to afford the title product which was used without further purification. 1H NMR (CDCl3) δ: 7.74 (s, 1H), 7.51 (s, 1H), 7.29-7.37 (m, 2H), 6.96 (s, 1H), 4.98 (br. s., 1H), 3.92 (s, 3H), 2.70-2.79 (m, 1H), 2.57-2.68 (m, 1H), 2.55 (br. s., 1H), 2.27-2.34 (m, 3H), 1.98-2.11 (m, 3H), 1.86-1.93 (m, 1H), 1.59 (s, 1H).